Supernus completes merger with Indivior, to trade under SUPN on Nasdaq

Supernus Pharmaceuticals announced the successful completion of its merger with Indivior Pharmaceuticals on November 2, 2026, and will begin trading on the Nasdaq Global Market under the ticker SUPN on November 3, 2026. The transaction creates a diversified biopharmaceutical company with an 11-product CNS-focused portfolio.

Detected & updated continuously · Source: Nebula